Événement sur demande

The Evolving Landscape of Cutaneous Squamous Cell Carcinoma Treatment: Updates on Immunotherapy Treatment

Date de première diffusion :
le mercredi 30 octobre 2019

Durée : 55:22 minutes

Mettant en vedette

Marcus Butler, M.D.

Cutaneous Squamous Cell Carcinoma (cSCC) is the second most common form of skin cancer in Canada, with an estimated 16,000+ patients nationally. It is forecasted that anywhere from 200-700 of these patients have locally advanced or metastatic cSCC.

This livestreaming program targets surgeons from a number of specialties that are involved in the treatment of cSCC patients, to advise on a new, recently approved curative treatment. Cemiplimab is a fully-human monoclonal antibody that is the first and only biologic immunotherapy treatment specifically approved and available for adult patients with metastatic or locally advanced cSCC.

Resources

Health Care Professional Resources

cSCC A Patient Guide EN

CEC Guide à l’intention des patients FR

Langue : Anglais

Domaine thérapeutique : Skin Cancer